1887

Journal of General Virology header logo

Volume 71, Issue 2

Epstein-Barr virus receptor expression on human CD8 (cytotoxic/suppressor) T lymphocytes Free

Abstract

In 1977 we showed that cells of a human lymphocytic leukaemia-derived T line (Molt-4) have receptors for Epstein-Barr virus (EBV). More recently, EBV- positive human T cell lymphomas have been recognized and human T cell lines containing the EBV genome have been established . To understand better the interaction of EBV with T cells, we decided to determine first whether human peripheral blood T lymphocytes express receptors for EBV. Using flow cytometry we examined the binding of both lymphocyte-transforming (B95-8) and non-transforming (P3HR-1) strains of EBV to T lymphocyte subpopulations, using a double labelling technique with T cell- specific phycoerythrinated monoclonal antibodies (Leu 2a) and fluoresceinated viral preparation. Our results suggest that, in general, about 50% of the CD8 (or suppressor/cytotoxic) T cell subpopulation from both EBV-seropositive and -seronegative individuals can bind EBV. EBV receptor expression on these T cells was about 10 and 51 times less than that on Molt-4 and Raji (an EBV receptor-positive B cell line) cells, respectively. The specificity of this binding was demonstrated by the inhibition of attachment of viral preparations preincubated with a monoclonal antibody directed against the viral ligand (gp240/350), and by preincubating these target T cells with unlabelled virus. We were unable to detect EBV-induced antigens in infected T cells, suggesting that, as in Molt-4 cells, virus internalization may not occur in fresh T cells and/or that the virus receptor may not be completely functional. We were also unable to detect C3d (or CR2) receptors on these T cells, or to inhibit virus attachment by treating the targets with an anti-CR2 monoclonal antibody (OKB7), suggesting that the EBV receptor on CD8 peripheral blood lymphocytes is different from that on B cells.

  • Received:
  • Accepted:
  • Published Online:
© Society for General Microbiology 1990
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-71-2-379
1990-02-01
2024-05-02
Loading full text...

Full text loading...

/deliver/fulltext/jgv/71/2/JV0710020379.html?itemId=/content/journal/jgv/10.1099/0022-1317-71-2-379&mimeType=html&fmt=ahah

References

  1. Anderson R. W., Volsky D. J., Greenberg B., Knox S.-J., Bechtold T., Kuszynski C., Harada S., Purtilo D. T. 1983; Lymphocyte abnormalities in preleukemia. I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors. Leukemia Research 7:389–396
     [Google Scholar]
  2. De Thé G., Geser A., Day N. E., Tukei P. M., Williams E. H., Beri D. P., Smith P. G., Dean A. G., Bornkamm G. W., Fearino P., Henle W. 1978; Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt’s lymphoma from Ugandan prospective study. Nature; London: 274756–761
     [Google Scholar]
  3. Fearon D. T. 1985; Human complement receptor for C3b (CR1) and C3b (CR2). Journal of Investigative Dermatology 85:53S–57S
     [Google Scholar]
  4. Fingeroth J. D., Weis J. J., Tedder T. F., Strominger J. D., Biro P. A., Fearon D. T. 1984; Epstein-Barr virus receptor of human B lymphocyte is the C3d receptor CR2. Proceedings of the National Academy of Sciences, U.S.A 81:4510–4514
     [Google Scholar]
  5. Fingeroth J. D., Clabby M. L., Strominger J. D. 1988; Characterization of a T-lymphocyte Epstein-Barr virus/C3d receptor (CD21). Journal of Virology 62:1442–1447
     [Google Scholar]
  6. Freeman C. B., Magrath I. T., Benjamin D., Makuch R., Douglass E. C., Santaella M. I. 1982; Classification of cell lines derived from undifferentiated lymphomas according to their expression of complement and Epstein-Barr virus receptors: implications for the relationship between African and American Burkitt’s lymphoma. Clinical Immunology and Immunopathology 25:103–113
     [Google Scholar]
  7. Greaves M. F., Brown G., Rickinson A. B. 1975; Epstein-Barr virus binding sites on lymphocytes subpopulation and the origin of lymphoblasts in cultured lymphoid cell lines and in the blood of patients with infectious mononucleosis. Clinical Immunology and Immunopathology 3:514–524
     [Google Scholar]
  8. Henle W., Diehl V., Kohn G., Zur Hausen H., Henle G. 1967; Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 157:1064–1065
     [Google Scholar]
  9. Henle G., Henle W., Diehl V. 1968; Relation of Burkitt tumor associated herpes-type virus to infectious mononucleosis. Proceedings of the National Academy of Sciences, U.S.A 59:94–101
     [Google Scholar]
  10. Hoffman G. J., Lazaroruitz S. G., Haywood S. O. 1980; MoAb against a 250000-dalton glycoprotein of EBV identifies a MA and neutralizing antigen. Proceedings of the National Academy of Sciences, U.S.A 77:2979–2983
     [Google Scholar]
  11. Hutt-Fletcher L. M., Fowler E., Lambris J. D., Ross G. D. 1983; Studies of the EBV receptor found on Raji cells. II. A comparison of lymphocyte binding sites for EBV and C3d. Journal of Immunology 130:1309–1312
     [Google Scholar]
  12. Iida K., Nadler L., Nussenzweig V. 1983; Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. Journal of Experimental Medicine 158:1021–1033
     [Google Scholar]
  13. Jondal M., Klein G. 1973; Surface markers on human B and T lymphocytes. Presence of Epstein-Barr virus receptors on B lymphocytes. Journal of Experimental Medicine 138:1365–1378
     [Google Scholar]
  14. Jondal M., Klein G., Oldstone M., Yefenof E. 1976; Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scandinavian Journal of Immunology 5:401–410
     [Google Scholar]
  15. Jones J. F., Shurin S., Abramowski C., Tubbs R. R., Sciotto C. G., Wahl R., Sands J., Gottman D., Katz B. Z., Sklar J. 1988; T cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. New England Journal of Medicine 318:733–741
     [Google Scholar]
  16. Jonsson V., Wells A., Klein G. 1982; Receptors for the complement C3d component and the Epstein-Barr virus are quantitatively co-expressed on a series of B-cell lines and their derived somatic cell hybrids. Cellular Immunology 72:263–276
     [Google Scholar]
  17. Katsuki T., Hinuma Y., Yamamoto N., Abo T., Kumayai K. 1977; Identification of the target cells in human B lymphocytes and transformation by Epstein-Barr virus. Virology 83:287–294
     [Google Scholar]
  18. Khélifa R., Menezes J. 1982; Use of fluoresceinated EBV to study EBV-lymphoid cell interactions. Journal of Virology 41:649–656
     [Google Scholar]
  19. Kikuta H., Taguchi Y., Tomizawa K., Kojima K., Kawamura N., Ishizaka A., Sakiyama Y., Matsumoto S., Imai S., Kinoshita T., Koizumi S., Osato T., Kobayashi I., Hamada I., Hirai K. 1988; Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature; London: 333455–457
     [Google Scholar]
  20. Leyvraz S., Henle W., Chahinian A. P., Perlmann C., Klein G., Gordon R. E., Rosenblum M., Holland J. F. 1985; Association of Epstein-Barr virus with thymic carcinoma. New England Journal of Medicine 312:1296–1299
     [Google Scholar]
  21. Menezes J., Jondal M., Leibold W., Dorval G. 1976; Epstein- Barr virus interactions with human lymphocyte subpopulations: virus adsorption, kinetics of expression of Epstein-Barr virus-associated nuclear antigen, and lymphocyte transformation. Infection and Immunity 13:303–310
     [Google Scholar]
  22. Menezes J., Seigneurin J. M., Patel P., Bourkas A., Lenoir G. 1977; Presence of EBV receptors, but absence of virus penetration, in cells of an EBV genome-negative human lymphoblastoid T line (Molt 4). Journal of Virology 22:816–821
     [Google Scholar]
  23. Nemerow G. R., Walfert R., Mcnaughton M. E., Cooper N. R. 1985; Identification and characterization of Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). Journal of Virology 55:347–351
     [Google Scholar]
  24. Patel P., Menezes J. 1981; Epstein-Barr virus (EBV)-lymphoid cell interactions. I. Quantification of EBV particles required for the membrane immunofluorescence assay and the comparative expression of EBV receptors on different human B, T and null cell lines. Journal of General Virology 53:1–11
     [Google Scholar]
  25. Purtilo D. T. 1987; EBV: the spectrum of its manifestation in human beings. Southern Medical Journal 80:943–947
     [Google Scholar]
  26. Reece E. R., Gartner J. G., Seemayer T. A., Joncas J. H., Pagano J. S. 1981; Epstein-Barr virus in a malignant lymphoproli- ferative disorder of B cells occurring after thymic epithelial transplantation for combined immunodeficiency. Cancer Research 41:4243–4247
     [Google Scholar]
  27. Saemundsen A. K., Albeek H., Hansen J. P. H. 1982; Epstein- Barr virus nasopharyngeal and salivary gland carcinomas in Greenland eskimos. British Journal of Cancer 46:721–728
     [Google Scholar]
  28. Schnipper L. E. 1981; The EBV and human lymphoproliferative disorders. Progress in Haematology 12:275–297
     [Google Scholar]
  29. Schwaber J. F., Klein G., Ernberg I., Rosen A., Lazarus H., Rosen S. F. 1980; Deficiency of Epstein-Barr virus (EBV) receptors on B lymphocytes from certain patients with common varied agammaglobulinemia. Journal of Immunology 124:2191–2196
     [Google Scholar]
  30. Shapiro I. M., Volsky D. J., Seamundson A., Anisimova E., Klein G. 1982; Infection of the human T cell derived leukemia line Molt-4 by Epstein-Barr virus (EBV): induction of EBV determined antigen and virus production. Virology 120:171–181
     [Google Scholar]
  31. Shearer W. T., Ritz J., Finegold M. J., Guerra I. C., Rosenblatt H. M., Lewis D. E., Pollack M. S., Taber L. H., Sumaya C. V., Grumet F. C., Cleary M. L., Warnke R., Sklar J. 1985; Epstein-Barr virus associated B cell proliferations of diverse clonal origins after bone marrow transplantation in a 12 year old patient with severe combined immunodeficiency. New England Journal of Medicine 312:1151–1159
     [Google Scholar]
  32. Siaw M. F. E., Nemerow G. R., Cooper N. R. 1986; Biochemical and antigenic analysis of the Epstein-Barr virus/C3d receptor (CR2). Journal of Immunology 136:4146–4151
     [Google Scholar]
  33. Stevenson M., Volsky B., Hedenskog M., Volsky D. 1986; Immortalization of human T lymphocytes after transfection of Epstein-Barr virus DNA. Science 223:980–984
     [Google Scholar]
  34. Steward S. S., Price G. B. 1986; Realtime acquisition, storage and display or collorated 3-parameter flow cytometric data. Cytometry 7:82–88
     [Google Scholar]
  35. Stocco R., Sauvageau G., Menezes J. 1988; Differences in Epstein-Barr virus (EBV) receptors expression on various human lymphoid targets and their significance to EBV-cell interaction. Virus Research 11:209–225
     [Google Scholar]
  36. Takimoto T., Sato H., Ogura H., Miyamata T., Glaser R. 1986; Superinfection of epithelial hybrid cell (D98/HR-1, NPC-KT and ADL/AH) with Epstein-Barr virus and the relationship to the C3d receptor. Cancer Research 46:2541–2544
     [Google Scholar]
  37. Tatsumi E., Harada S., Kuszynski C., Volsky D., Minowada J., Purtilo D. T. 1985; Catalogue of Epstein-Barr virus (EBV) receptor on human malignant and non-malignant hematopoietic cell lines. Leukemia Research 9:231–238
     [Google Scholar]
  38. Tedder T. F., Clement L. T., Cooper M. D. 1984; Expression of C3d receptor during human B cell differentiation: immunofluorescence analysis with HB5 monoclonal antibody. Journal of Immunology 133:678–683
     [Google Scholar]
  39. Wells A., Steen H. B., Godal T., Klein G. 1981; Epstein-Barr virus receptor expression is correlated to cell cycle phase. Journal of Receptor Research 2:285–298
     [Google Scholar]
  40. Yefenof E., Klein G., Jondal M., Oldstone M. 1976; Surface markers on human B- and T-lymphocytes. IX. Two-color immuno-fluorescence studies on the association between EBV receptors and complement receptors on the surface of lymphoid cell line. International Journal of Cancer 17:693–700
     [Google Scholar]
  41. Yefenof E., Klein G., Kvarnung K. 1977; Relationship between complement activation, complement binding, and EBV adsorption by human hematopoietic cell line. Cellular Immunology 31:225–233
     [Google Scholar]
  42. Zur Hausen H., Schulte-Holthausen H., Klein G. 1970; EBV DNA in biopsies of Burkitt tumors and anaplastic carcinomas of the nasopharynx. Nature; London: 2281056–1058
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-71-2-379
Loading
Epstein-Barr virus receptor expression on human CD8+ (cytotoxic/suppressor) T lymphocytes
J. Gen. Virol. 71, 379 (1990); https://doi.org/10.1099/0022-1317-71-2-379
/content/journal/jgv/10.1099/0022-1317-71-2-379
/content/journal/jgv/10.1099/0022-1317-71-2-379
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error